Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Otamixaban HCl is an experimental injectable anticoagulant direct factor Xa inhibitor, that was investigated for the treatment for acute coronary syndrome. In 2013, Sanofi announced that it had ended development of the drug candidate after poor performance in a Phase III clinical trial.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | Otamixaban HCl is an experimental injectable anticoagulant direct factor Xa inhibitor, that was investigated for the treatment for acute coronary syndrome. In 2013, Sanofi announced that it had ended development of the drug candidate after poor performance in a Phase III clinical trial. |
Molecular Weight | 482.97 |
Formula | C25H27ClN4O4 |
CAS No. | 409081-12-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Otamixaban HCl 409081-12-5 RPR-130673 HCl RPR130673 HCl RPR 130673 HCl inhibitor inhibit